



The Max
Foundation

GIST Strategy

September 2017



Our **mission** is to increase global access to treatment, care and support for people living with cancer.

In memory of Max Rivarola, 1973-1991

Commitment to the Sustainable Development Goals

- The Max Foundation supports the Sustainable Development Goal #3 by aiming to decrease premature mortality from cancer
- Although today's major program focusses on chronic myeloid leukemia (CML), **the organization's portfolio also includes treatment for gastrointestinal stromal tumor (GIST)**, renal cell carcinoma (RCC), and other rare cancers
- GIST is the second largest disease area of work for the organization



The Max Foundation GIST Strategy

- Aims to decrease premature mortality from GIST in neglected populations of the world through humanitarian access to treatment, care and support

Partner with us in our mission by giving today at themaxfoundation.org/donate


themaxfoundation.org • facebook.com/themaxfoundation • [@stompoutcancer](https://twitter.com/stompoutcancer)



Access to Treatment for GIST in LMIC

Novartis – Max Partnership, 15 years of leadership in access programs


Previous international donations



GIPAP's international donation paradigm



GIPAP Case Management Cycle



Facts about GIST in GIPAP

- ✓ Since 2001 Novartis has provided access to Glivec through GIPAP to more than 11,000 GIST patients
- ✓ Currently more than 3,300 GIST patients are still in GIPAP (4 GIST patients have been in GIPAP since 2002)
- ✓ On average we approve 800 GIST patients every year in GIPAP: 500 of these have unresectable/metastatic GIST and 300 have adjuvant GIST
- ✓ 34 countries have only 1 physician who treats GIST




Facts about GIST in GIPAP

- ✓ Since 2001 Novartis has provided access to Glivec through GIPAP to more than 11,000 GIST patients
- ✓ Currently more than 3,300 GIST patients are still in GIPAP (4 GIST patients have been in GIPAP since 2002)
- ✓ On average we approve 800 GIST patients every year in GIPAP: 500 of these have unresectable/metastatic GIST and 300 have adjuvant GIST
- ✓ 34 countries have only 1 physician who treats GIST
- ✓ GIST patients represent 10 percent of the GIPAP population



Decreasing Premature Mortality from GIST through access to Glivec

Percentage of GIST patients in GIPAP by number of years on Glivec



Reimagining what is possible

Novartis – Max Partnership 2017 and beyond



Reimagining what is possible

Novartis – Max Partnership 2017 and beyond

CMLPath to Care™ collaboration replaces GIPAP with a new, independent, patient-centered access model as a Max Access Solution


The Max Foundation to lead humanitarian program for patients and oversee supply chain management; Novartis to contribute funding and product donation

Complex transition including oversight of 34,000 patients, 1,400 physicians, and 450 treatment centers in more than 75 countries on 4 continents that comprised GIPAP



Max Access Solution Model

A patient centered system of humanitarian access to oncology treatment



Pfizer – Max Collaboration

Max Access Solution for Sutent



- Name: Hisham
- Country: Sudan
- Diagnosis: GIST
- Age at diagnosis: 32
- Family: wife and 2 young girls
- Treatment: 5 years on imatinib, in need of sunitinib in 2014

In 2015 Pfizer signed a Collaboration Agreement with The Max Foundation for a pilot program on access to Sutent for patients in lowest income economies who were prescribed the treatment and otherwise had no other means to access it.






Supporting GIST Patients in Low and Middle Income Countries

Max Access Solution for GIST, 2017

The Good



NOVARTIS

PFIZER

OTSUKA

TAKEDA

2017

Humanitarian Partnership
for Access to Cancer Treatment

INCYTE

PINT

BRISTOL-MYERS
SQUIBB

ARIAD


2017 Humanitarian PACT for GIST




Countries eligible for Glivec & Sutent



All Countries with active GIST



The Bad



PATIENT CANNOT DISCLOSE THE DIAGNOSIS TO EMPLOYER THUS UNABLE TO ASK FOR TIME OFF

PATIENT AND HOSPITAL CANNOT AFFORD IMPORT FEES

MANUFACTURER DOES NOT HAVE A PATHWAY TO PROVIDE HUMANITARIAN ACCESS

PRODUCT AVAILABLE VIA DONATION BUT PATIENT CANNOT AFFORD DIAGNOSTICS

IMPORTATION PROCESS CUMBERSOME AND SLOW PRODUCES INTERRUPTION OF TREATMENT

HOSPITAL DISPENSING AND STORING FACILITIES DO NOT MEET INTERNATIONAL SUPPLY CHAIN REGULATIONS AND STANDARDS

CAN AFFORD ONLY FOR A FEW MONTHS

PRIVATE HEALTH INSURANCE DOESN'T COVER IT

CAN'T AFFORD CO-PAY

CAN'T AFFORD PRIVATE PURCHASE

PRODUCT NOT REGISTERED IN THE COUNTRY

COUNTRY DOES NOT HAVE UNIVERSAL HEALTH CARE

GOVERNMENT DOES NOT LICENSE

PRODUCT NOT IN THE COUNTRY'S NATIONAL LIST

GOVERNMENT IMPOSES TAXES ON IMPORTED PRODUCTS FOR DONATION

PRODUCT NOT COMMERCIALIZED IN THE COUNTRY

COUNTRY DOES NOT ALLOW INTERNATIONAL DONATION OF MEDICINES

SURGERY CAPABILITIES AND SAFE BLOOD PRODUCTS NOT AVAILABLE IN THE COUNTRY

DIAGNOSTIC CAPABILITIES NOT AVAILABLE IN THE COUNTRY

SUBSTANDARD GOVERNMENT PROGRAMS

PATIENT CANNOT AFFORD HOSPITAL CONSULT


PRODUCT AVAILABLE VIA DONATION BUT PATIENT CANNOT AFFORD BUS FARE TO HOSPITAL

PATIENT CANNOT AFFORD TO TAKE THE DAY OFF TO ATTEND THE CONSULT


PATIENT CANNOT AFFORD A PLACE TO STAY FOR CLOSE TO THE HOSPITAL



The Ugly




Countries with no infrastructure to treat GIST



- South Sudan
- Comoros
- Guinea-Bissau
- Somalia
- Burundi
- Eritrea
- Liberia
- Afghanistan
- Chad
- Gambia
- Mozambique
- Guinea



How can each of us...
Contribute to the Good
Improve the Bad
Change the Ugly



Dr. Damira Bayzakova, Kyrgyzstan

“Providing lifesaving treatment to one patient does not save the life of one patient – it saves the lives of the dozens of small children and elderly family members who depend on that patient for their survival.”

Partner with us in our mission by giving today at themaxfoundation.org/donate

themaxfoundation.org • facebook.com/themaxfoundation • [@stompoutcancer](https://twitter.com/stompoutcancer)





THANK YOU!



The Max
Foundation

themaxfoundation.org • facebook.com/themaxfoundation • [@stompoutcancer](https://twitter.com/stompoutcancer)